See more : New Residential Investment Corp. (NRZ-PB) Income Statement Analysis – Financial Results
Complete financial analysis of Solara Active Pharma Sciences Limited (SOLARA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Solara Active Pharma Sciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nedap N.V. (0NNU.L) Income Statement Analysis – Financial Results
- New Gold Inc. (NGD.TO) Income Statement Analysis – Financial Results
- Personal Assets Trust plc (PNL.L) Income Statement Analysis – Financial Results
- Far East Horizon Limited (3360.HK) Income Statement Analysis – Financial Results
- Kerur Holdings Ltd. (KRUR.TA) Income Statement Analysis – Financial Results
Solara Active Pharma Sciences Limited (SOLARA.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.solara.co.in
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, loop diuretic, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, topical anti-infectives, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, nucleoside inhibitor, aprepitant, NSAIDs, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company also exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.74B | 14.44B | 12.68B | 15.76B | 12.68B | 13.22B | 5.21B | 9.41B |
| Cost of Revenue | 8.39B | 7.89B | 6.54B | 7.70B | 6.41B | 7.47B | 4.47B | 5.03B |
| Gross Profit | 4.36B | 6.55B | 6.14B | 8.06B | 6.27B | 5.75B | 736.27M | 4.38B |
| Gross Profit Ratio | 34.19% | 45.37% | 48.45% | 51.16% | 49.45% | 43.51% | 14.13% | 46.58% |
| Research & Development | 0.00 | 355.90M | 540.90M | 529.10M | 474.70M | 440.50M | 18.18M | 0.00 |
| General & Administrative | 243.30M | 774.60M | 347.70M | 329.20M | 316.20M | 176.40M | 412.90M | 204.00K |
| Selling & Marketing | 341.80M | 8.60M | 53.90M | 56.20M | 72.10M | 63.10M | 7.48M | -187.00K |
| SG&A | 2.50B | 783.20M | 401.60M | 385.40M | 388.30M | 239.50M | 420.38M | 17.00K |
| Other Expenses | 3.41B | 225.50M | 200.20M | 84.60M | 107.90M | 74.60M | -7.87M | 116.13M |
| Operating Expenses | 4.00B | 6.32B | 6.47B | 5.23B | 4.62B | 4.24B | 446.43M | 3.80B |
| Cost & Expenses | 12.38B | 14.21B | 13.01B | 12.93B | 11.03B | 11.71B | 4.92B | 8.83B |
| Interest Income | 22.20M | 57.80M | 77.60M | 142.20M | 76.20M | 16.10M | 3.30M | 0.00 |
| Interest Expense | 1.04B | 900.60M | 752.80M | 802.40M | 676.50M | 730.90M | 251.36M | 284.97M |
| Depreciation & Amortization | 1.03B | 1.11B | 1.12B | 1.08B | 933.70M | 824.30M | 339.83M | 551.13M |
| EBITDA | -2.82B | 1.52B | 885.00M | 4.14B | 2.86B | 2.32B | 626.33M | 1.22B |
| EBITDA Ratio | -22.15% | 10.84% | 7.88% | 25.90% | 21.34% | 16.98% | 12.09% | 13.30% |
| Operating Income | -1.98B | 85.60M | -332.80M | 2.62B | 1.71B | 1.51B | 289.84M | -33.00K |
| Operating Income Ratio | -15.55% | 0.59% | -2.62% | 16.61% | 13.46% | 11.40% | 5.56% | 0.00% |
| Total Other Income/Expenses | -2.90B | -779.80M | -578.20M | -612.20M | -543.80M | -827.10M | -231.57M | -584.45M |
| Income Before Tax | -4.88B | -448.10M | -911.00M | 2.22B | 1.15B | 676.70M | 58.27M | 384.52M |
| Income Before Tax Ratio | -38.33% | -3.10% | -7.18% | 14.06% | 9.06% | 5.12% | 1.12% | 4.09% |
| Income Tax Expense | 785.40M | -225.70M | -328.10M | 1.50M | 3.90M | 5.80M | -1.40M | 84.37M |
| Net Income | -5.67B | -221.70M | -581.50M | 2.21B | 1.15B | 595.10M | 3.77M | 301.64M |
| Net Income Ratio | -44.53% | -1.54% | -4.58% | 14.05% | 9.04% | 4.50% | 0.07% | 3.20% |
| EPS | -145.27 | -6.16 | -16.18 | 69.00 | 44.29 | 24.10 | 0.34 | 26.94 |
| EPS Diluted | -145.27 | -6.16 | -16.18 | 64.53 | 42.82 | 24.07 | 0.34 | 26.94 |
| Weighted Avg Shares Out | 39.06M | 36.00M | 35.94M | 32.09M | 25.88M | 24.69M | 11.20M | 11.20M |
| Weighted Avg Shares Out (Dil) | 39.06M | 36.00M | 35.94M | 34.31M | 26.77M | 24.73M | 11.20M | 11.20M |
Source: https://incomestatements.info
Category: Stock Reports